Tours and Reception

Join fellow attendees as they tour renowned local research facility, a former Merck Research Laboratory, followed by a delightful reception at the Kirin Pharma USA.

Alexandria Real Estate Equities, Inc. will host BioParks 2008 attendees to visit a former Merck Research Laboratories building that is Green and LEED certified. In addition to an in depth tour of this building, Alexandria representatives will present storyboards on Green and LEED certifications as well as operations and practices needed to be sustainable.

Alexandria Real Estate Equities, Inc. (ARE-NYSE) is the largest owner and pre-eminent first-in-class international real estate investment trust focused principally on the ownership, operation, management, acquisition, redevelopment, and selective development of properties containing office/laboratory space. Alexandria is the leading provider of real estate to the life science industry, and has an outstanding nine-year track record as a NYSE listed company with an approximate $5.1 billion total market capitalization (as of December 31, 2006). Alexandria provides high-quality real estate, technical infrastructure, services and capital to the broad and diverse life science sector. Client tenants include institutional (universities and independent non-for-profit institutions), pharmaceutical, biotechnology, medical device, life science product, service, biodefense and translational research entities, as well as government agencies. Alexandria’ international operating platform is based on the principle of “clustering,” with assets and operations strategically located in key life science hub markets.

Kirin Pharma USA, Inc. Kirin Pharma USA, Inc. is a wholly owned U.S. subsidiary of Kirin Pharma Company, Ltd. of Japan and acts as Kirin Pharma’s sole agent in the U.S., facilitating the company's pharmaceutical development efforts in North America. Our research goals focus on the following core therapeutic areas: Cancer, renal diseases, immune disorders, hematological & infectious diseases. In addition to supporting the company’s internal programs, Kirin Pharma USA continuously searches for novel technologies and pharmaceutical products which represent licensing and/or partnering opportunities complementary to Kirin Pharma’s drug development pipeline. Kirin Pharma USA’s key areas of partnering include immune disorders and infectious diseases, as well as cancer, renal diseases, and hematological disorders in an effort to support Kirin Pharma’s business platforms. Kirin Pharma USA seeks product candidates at any stage of development, and partners from both the academic and industrial sectors who have novel technologies that can facilitate Kirin Pharma USA’s and Kirin Pharma’s research and development efforts.